Showing 828 results
-
Media Release /- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…
-
Media Release /2005 Release SubHeadlineBody Copy Here
-
Media Release /- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class…
-
Media Release /- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,…
-
Media Release /- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…
-
Media Release /- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1)- Findings…
-
Media Release /- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with…
-
Media Release /- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer- Plenary session to highlight impact…
-
Media Release /Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damagesJury decides in favor of Novartis and rejects claims for punitive damagesNPC maintains it reported true and…
-
Media Release /- Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care- Study did not meet primary endpoint at 1 year,…
